Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02268214
Registration number
NCT02268214
Ethics application status
Date submitted
15/10/2014
Date registered
20/10/2014
Date last updated
13/09/2018
Titles & IDs
Public title
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus
Query!
Secondary ID [1]
0
0
2013-004674-97
Query!
Secondary ID [2]
0
0
MB102-229
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DEPICT 1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 1 Diabetes Mellitus
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Placebo for dapagliflozin
Experimental: Arm A: Dapagliflozin - Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
Experimental: Arm B: Dapagliflozin - Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
Placebo comparator: Arm C: Placebo for Dapagliflozin - Placebo tablet orally, once daily for 52 weeks
Treatment: Drugs: Dapagliflozin
Tablets
Treatment: Drugs: Placebo for dapagliflozin
Tablets
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adjusted Mean Change in HbA1c From Baseline at Week 24
Query!
Assessment method [1]
0
0
Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model\[RMM\]).
Query!
Timepoint [1]
0
0
From Baseline to Week 24
Query!
Secondary outcome [1]
0
0
Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24
Query!
Assessment method [1]
0
0
Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model\[RMM\])
Query!
Timepoint [1]
0
0
From Baseline to Week 24
Query!
Secondary outcome [2]
0
0
Adjusted Mean Percent Change in Body Weight From Baseline at Week 24
Query!
Assessment method [2]
0
0
Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model\[RMM\])
Query!
Timepoint [2]
0
0
From Baseline to Week 24
Query!
Secondary outcome [3]
0
0
Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24
Query!
Assessment method [3]
0
0
Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model\[RMM\])
Query!
Timepoint [3]
0
0
From Baseline to Week 24
Query!
Secondary outcome [4]
0
0
Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24
Query!
Assessment method [4]
0
0
Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
Query!
Timepoint [4]
0
0
From Baseline to Week 24
Query!
Secondary outcome [5]
0
0
Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24
Query!
Assessment method [5]
0
0
Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose \> 70 and \<= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model\[RMM\])
Query!
Timepoint [5]
0
0
From Baseline to Week 24
Query!
Secondary outcome [6]
0
0
Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events
Query!
Assessment method [6]
0
0
Subjects with HbA1c reduction from baseline to week 24 (LOCF) \>= 0.5% and without severe hypoglycemia events
Query!
Timepoint [6]
0
0
From Baseline to Week 24
Query!
Eligibility
Key inclusion criteria
* Diagnosis of Type 1 Diabetes mellitus (T1DM)
* Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)
* Insulin use for at least 12 months per patient reported or medical records
* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening
* Subjects must be on a total insulin dose of = 0.3 U/kg/day for at least 3 months prior to screening
* If on MDI insulin administration, subject must be on = 3x injections per day
* Screening Visit: Central laboratory HbA1c = 7.7% and = 11.0%
* Body mass index (BMI) = 18.5 kg/m2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity
* Taking metformin and/or thiazolidinediones within 2 months prior to screening
* Taking any antidiabetic medication (other than insulin), within 1 month prior to screening
- Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration
* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening
* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening
* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening
* History of Addison's disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/11/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
833
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Concord
Query!
Recruitment hospital [2]
0
0
Research Site - Daw Park
Query!
Recruitment hospital [3]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [4]
0
0
Research Site - Heidelberg West
Query!
Recruitment hospital [5]
0
0
Research Site - Newcastle
Query!
Recruitment hospital [6]
0
0
Research Site - Southport
Query!
Recruitment hospital [7]
0
0
Research Site - Wollongong
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
0
0
3081 - Heidelberg West
Query!
Recruitment postcode(s) [5]
0
0
2291 - Newcastle
Query!
Recruitment postcode(s) [6]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [7]
0
0
2500 - Wollongong
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maine
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Innsbruck
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Saint Stefan/Stainz
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Wien
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Bonheiden
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Leuven
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Liege
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
British Columbia
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Manitoba
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Arhus C
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Esbjerg
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Odense
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Randers NØ
Query!
Country [35]
0
0
Finland
Query!
State/province [35]
0
0
Helsinki
Query!
Country [36]
0
0
Finland
Query!
State/province [36]
0
0
Jyvaskyla
Query!
Country [37]
0
0
Finland
Query!
State/province [37]
0
0
Kuopio
Query!
Country [38]
0
0
Finland
Query!
State/province [38]
0
0
Oulu
Query!
Country [39]
0
0
Finland
Query!
State/province [39]
0
0
Tampere
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Besançon Cedex
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Corbeil-Essonnes
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Dijon
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
SAINT HERBLAIN Cedex
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Vandoeuvre les Nancy
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Aschaffenburg
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Aßlar
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Bad Oeynhausen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Falkensee
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Munich
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Munster
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Neuwied
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Oldenburg
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Pohlheim
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Schweinfurt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Sulzbach
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Witten
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Baja
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Balatonfured
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Budapest
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Létavértes
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Szeged
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Zalaegerszeg
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Haifa
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Jerusalem
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Safed
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Tel-Aviv
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Tikva
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Firenze
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Milano
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Padowa
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Palermo
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Ravenna
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Sesto San Giovanni
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Siena
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Aguascalientes
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Chihuahua
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
Cuernavaca
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
Guadalajara
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Merida
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Mexico
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Monterrey
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
Torreon
Query!
Country [83]
0
0
Mexico
Query!
State/province [83]
0
0
Zapopan, Jalisco
Query!
Country [84]
0
0
Mexico
Query!
State/province [84]
0
0
Zapopan
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Bucuresti
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Dolj
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Galati
Query!
Country [88]
0
0
Romania
Query!
State/province [88]
0
0
Iasi
Query!
Country [89]
0
0
Romania
Query!
State/province [89]
0
0
Timisoara
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
A Coruña
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Almeria
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Barcelona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Sevilla
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Valencia
Query!
Country [95]
0
0
Sweden
Query!
State/province [95]
0
0
Göteborg
Query!
Country [96]
0
0
Sweden
Query!
State/province [96]
0
0
Karlstad
Query!
Country [97]
0
0
Sweden
Query!
State/province [97]
0
0
Lund
Query!
Country [98]
0
0
Sweden
Query!
State/province [98]
0
0
Uppsala
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Belfast
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Chesterfield
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Dundee
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Nottingham
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Sheffield
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Welwyn Garden City
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Bristol-Myers Squibb
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02268214
Query!
Trial related presentations / publications
Melin J, Tang W, Rekic D, Hamren B, Penland RC, Boulton DW, Parkinson J. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus. J Clin Pharmacol. 2022 Oct;62(10):1227-1235. doi: 10.1002/jcph.2062. Epub 2022 May 2. Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto E, Mathieu C. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020 Oct;8(10):845-854. doi: 10.1016/S2213-8587(20)30280-1. Mathieu C, Dandona P, Birkenfeld AL, Hansen TK, Iqbal N, Xu J, Repetto E, Scheerer MF, Thoren F, Phillip M. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index >/=27 kg/m2. Diabetes Obes Metab. 2020 Nov;22(11):2151-2160. doi: 10.1111/dom.14144. Epub 2020 Aug 20. Parkinson J, Tang W, Astrand M, Melin J, Ekholm E, Hamren B, Boulton DW. Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes Obes Metab. 2019 Jun;21(6):1381-1387. doi: 10.1111/dom.13664. Epub 2019 Mar 14. Dandona P, Mathieu C, Phillip M, Hansen L, Tschope D, Thoren F, Xu J, Langkilde AM; DEPICT-1 Investigators. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018 Dec;41(12):2552-2559. doi: 10.2337/dc18-1087. Epub 2018 Oct 23. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, Thoren F, Xu J, Langkilde AM; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Erratum In: Lancet Diabetes Endocrinol. 2017 Dec;5(12):e8. doi: 10.1016/S2213-8587(17)30375-3.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Anna Maria Langkilde
Query!
Address
0
0
AstraZeneca
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02268214
Download to PDF